Photobiomodulation (PBM) can prevent or reduce the severity and duration of oral mucositis.
The effect of Photobiomodulation Therapy (PBMT) previously known as Low Level Laser Therapy (LLLT) on oral mucositis has been reported in over 30 randomised controlled clinical trials. These includes patients undergoing chemotherapy, radiotherapy or haematopoietic stem cell transplantation (HSCT) in both pediatric and and adult populations. These studies have shown that PBMT can be prevent as well as reduce the severity and duration of oral mucositis.
Photobiomodulation (PBM) therapy, (previously known as Low Level Laser Therapy or LLLT) is the application of light to tissues to reduce inflammation and improve healing. It works by increasing cellular energy (ATP) and reducing free radicals (oxidative stress). There are over 700 randomised controlled clinical trials published on PBM for a wide range of painful and non-healing applications including 32 controlled clinical trials on oral mucositis.
Light at specific wavelengths, can penetrate cells and activate the mitochondria, leading to increased cellular energy production, which is critical to cellular health, increased ATP energy levels and longevity.
The mitochondria organelles represent the batteries that fuel ALL the processes of our organs.
More cellular energy inside the cell = Optimum organ functionality
Clinical trials show a significant improvement in healing of wounds and reduction of pain.
A recent systematic review on PBM for OM found that it reduces pain, severity and duration of chemotherapy and radiotherapy induced oral mucositis.
Multinational Association of Supportive Care in Cancer (MASCC) Recommendations
The Multinational Association of Supportive Care in Cancer (MASCC) recommends the use of intra-oral PBM therapy using low level laser therapy for the prevention of Oral Mucositis
Adult patients receiving HSCT conditioned with high dose chemotherapy (CT), with or without total body irradiation
Adult patients receiving radiotherapy (RT) to the head & neck without CT
Adult patients receiving RT and CT for head and neck cancer
ABOUT US
CosmoAesthetics™ (“CA”) is an Australian based innovation hub founded in 2015 by Dr. Mathew Jafarzadeh and is focused on developing disruptive technologies to provide home-based health care products and services for consumers globally.
© 2021 BY COSMOAESTHETICS